AstraZeneca makes deal with White House to lower drug prices
AstraZeneca became the second drugmaker to enter a deal with the Trump administration to offer lower prices to Medicaid and to offer some of its drugs at a discount through TrumpRx, a government website to facilitate sales directly to consumers.
“In other words the lowest price anywhere in the world, that’s what we get,” President Trump said during an Oval Office press conference Friday. The centerpiece of the deal is most-favored-nation pricing for drugs sold to Medicaid. That would link Medicaid prices to the lower ones paid in other developed countries.
As part of the deal, AstraZeneca will also offer discounts of up to 80% off list prices on direct sales to consumers, according to a company statement. Its drugs include inhalers like Bevespi Aerosphere for people with COPD and Airsupra for people with asthma. AstraZeneca, based in the U.K., also said it would expand drug manufacturing and research in the U.S.
In return for these commitments, the drug company will get a three-year exemption from certain tariffs.
The White House unveiled its plan for TrumpRx and a similar deal with Pfizer on Sept. 30. The website will help patients access drugs at lower prices — bypassing health insurance.
TrumpRx is part of a broader initiative the administration says is aimed at bringing prices paid by Americans more in line with those paid in other developed countries.
The announcement follows an executive order in May, and letters to 17 pharmaceutical companies sent out over the summer to push them to lower prices voluntarily.
The TrumpRx website is expected to launch sometime in 2026, and would take consumers to pharmaceutical companies’ direct-to-consumer websites to fulfill orders.
The impact of the Trump administration deals with pharmaceutical companies for consumers is unclear. Medicaid and its beneficiaries, for instance, already pay some of the lowest prices for drugs. And people with health insurance could spend less on their medicines through copays than buying them directly from AstraZeneca.
AstraZeneca also said Thursday that it would invest an additional $500 million in a new manufacturing facility in Virginia, raising the investment to $4.5 billion. That’s part of a $50 billion investment announced in July to expand manufacturing facilities in California, Indiana, Maryland, Massachusetts, Texas and Virginia, as well as other research and development efforts.
“For all the pharmaceutical companies out there — we’re talking to all of you, pick up a shovel,” said Dr. Mehmet Oz, who leads the Centers for Medicare and Medicaid Services, during the press conference.
Trump said his administration had gotten a total of $18 trillion total commitments to re-shore pharmaceutical manufacturing. NPR wasn’t immediately able to independently confirm that number.
Macron puts Lecornu back as France’s prime minister just days after he quit
French President Emmanuel Macron has reappointed Sébastien Lecornu as prime minister, just days after his resignation, asking him to try again to form a government and produce a budget.
National Guard troops begin patrols in Memphis
Guard members in Memphis are operating under the governor's command — unlike other cities facing troop deployments, including Los Angeles, Portland and Chicago.
Peru: Chicha Cumbia, the electric pulse of Lima
Photographers and storytellers Karla Gachet and Ivan Kashinsky document cumbia music in Colombia, Mexico, Ecuador, Peru, Argentina and the United States.
White House says ‘substantial’ layoffs of federal workers have begun, with few details
The Trump administration says it has started the process of issuing reduction-in-force notices to federal employees. It's not clear how many agencies are affected or how many people.
More than 20 kids in India have died from contaminated cough syrup. Who’s to blame?
The cough syrup was contaminated with industrial chemicals. Experts say this is no accident. It's the latest case of what is being called a global crime.
Every moment pops in the nuclear thriller ‘A House of Dynamite’
A single nuclear warhead, of unknown origin, is heading toward the U.S. mainland in Kathryn Bigelow's new Netflix film. It's an unnerving scenario — but it's also thrilling to watch.
